Zentiva AG Acquires Majority Stake in APONTIS PHARMA

Zentiva AG has successfully acquired approximately 85.27% of the voting rights and 83.57% of the share capital of APONTIS PHARMA AG. This follows the closure of the acceptance period for its public purchase offer on November 21, 2024. Zentiva, operating under Zentiva Pharma GmbH, sees this acquisition as a significant step toward expanding its pharmaceutical reach and enhancing its ability to provide affordable medicines across Europe.

Steffen Saltofte, CEO of Zentiva, expressed satisfaction with the acquisition, emphasizing the strategic move to unify strengths and execute long-term plans. However, the finalization of the acquisition is pending approval under foreign direct investment control in Germany, with settlement anticipated by December 2024 or first quarter of 2025.